Results 21 to 30 of about 60,286 (337)

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo

Scientific Reports, 2021
FDA-approved anti-PD-L1 antibody drug Atezolizumab is a human IgG1 without glycosylation by an N297A mutation. Aglycosylation of IgG1 has been used to completely remove the unwanted Fc-mediated functions such as antibody-dependent cytotoxicity (ADCC ...
Maohua Li, Rongqing Zhao, Jianxin Chen, Wenzhi Tian, Chenxi Xia, Xudong Liu, Yingzi Li, Song Li, Hunter Sun, Tong Shen, Wenlin Ren, Le Sun   +11 more
doaj   +1 more source

Immune checkpoint inhibitors in renal cell carcinoma [PDF]

, 2017
The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core   +1 more source

Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC

New England Journal of Medicine, 2018
BACKGROUND The cancer‐cell–killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor–mediated immunosuppression with bevacizumab.
M. Socinski, R. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodríguez-Abreu, D. Moro-Sibilot, C. Thomas, F. Barlesi, G. Finley, C. Kelsch, Anthony Lee, S. Coleman, Yu Deng, Yijing Shen, M. Kowanetz, A. López-Chávez, A. Sandler, M. Reck   +19 more
semanticscholar   +1 more source

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab

Frontiers in Oncology, 2022
ObjectiveRecently, the significant improvement of atezolizumab and pembrolizumab over chemotherapy for treatment-naïve stage IV non-small cell lung cancer (NSCLC) has been demonstrated, but the cost-effectiveness of these regimens remains unknown ...
Shen Lin, Yiyuan Li, Dian Gu, Shaohong Luo, Xiaoting Huang, Liangliang Dong, Xiongwei Xu, Peili Lin, Xiuhua Weng   +8 more
doaj   +1 more source

First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer

New England Journal of Medicine, 2018
BACKGROUND Enhancing tumor‐specific T‐cell immunity by inhibiting programmed death ligand 1 (PD‐L1)–programmed death 1 (PD‐1) signaling has shown promise in the treatment of extensive‐stage small‐cell lung cancer.
L. Horn, A. Mansfield, A. Szczesna, L. Havel, M. Krzakowski, M. Hochmair, F. Huemer, G. Losonczy, M. Johnson, M. Nishio, M. Reck, T. Mok, S. Lam, D. Shames, Juan Liu, B. Ding, A. López-Chávez, F. Kabbinavar, W. Lin, A. Sandler, Stephen V. Liu   +20 more
semanticscholar   +1 more source

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Journal of Clinical Oncology, 2023
PURPOSE In the treatment of non–small-cell lung cancer (NSCLC) with a driver mutation, the role of anti–PD-(L)1 antibody after tyrosine kinase inhibitor (TKI) remains unclear.
Sehhoon Park, Tae Min Kim, Ji-Youn Han, Gyeong-Won Lee, B. Shim, Yun-Gyoo Lee, Sang-We Kim, I. Kim, Suee Lee, Yu-Jung Kim, Ji Hyun Park, Sang-Gon Park, K. Lee, E. Kang, Ju Won Kim, Seong-Hun Shin, C. Ock, Byung-Ho Nam, Jaebong Lee, H. Jung, Jong-Mu Sun, Se-Hoon Lee, J. Ahn, Myung-Ju Ahn   +23 more
semanticscholar   +1 more source

Atezolizumab in combination with bevacizumab for the management of patients with hepatocellular cancer in the first-line setting: systematic literature review and meta-analysis

Liver Cancer, 2023
Background & aims: The objective of this systematic literature review (SLR) and network meta-analysis (NMA) is to compare randomised controlled trial evidence for atezolizumab-bevacizumab with globally relevant pharmacological comparators for first-line
Arndt Vogel, Richard S. Finn, Marie-Hélène Blanchet Zumofen, Carolina Heuser, Javier Sanchez Alvarez, Michael Leibfried, Catherine R. Mitchell, Sarah Batson, Gabrielle Redhead, Vincent E. Gaillard, Masatoshi Kudo   +10 more
doaj   +1 more source

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. [PDF]

, 2019
BackgroundNovel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, a programmed death 1 inhibitor ...
Bajorin, DF, Bellmunt, J, Choueiri, TK, Climent, MA, Culine, S, de Wit, R, Fong, L, Fradet, Y, Frenkl, TL, Gerritsen, W, Gurney, H, Lee, JL, Nam, K, Necchi, A, Perini, RF, Petrylak, DP, Quinn, DI, Sternberg, CN, Vaughn, DJ, Vogelzang, NJ   +19 more
core   +1 more source

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Journal for ImmunoTherapy of Cancer, 2019
Background The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients.
Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin, Sandhya Girish   +12 more
doaj   +1 more source

Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]

, 2016
With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S., Carideo, Luciano, Galli, Filippo, Lauri, Chiara, Pacilio, Massimiliano, Signore, Alberto, Valabrega, Stefano   +6 more
core   +2 more sources